The UK and US have secured a important bilateral deal that will preserve no levies on UK drug shipments being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This pledge ensures that tariffs on these crucial goods will be held at nothing for a duration of the next three years.
This deal is in response to recent statements to significantly raise tariffs on branded pharmaceutical imports, with potential rates floated up to one hundred percent.
"This agreement with the UK reinforces the worldwide climate for new treatments and introduces long-overdue balance to U.S.–U.K. medicine commerce," a statement noted.
Commercial Importance
Medicines constitute one of the UK's most significant goods shipped to the America, which is clearly the primary market for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to the third quarter, the UK sold medicines worth over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This agreement secures jobs, stimulates capital expenditure and facilitates the UK to become a international leader for medical research," a minister stated.
Specific UK Commitments
The deal includes several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments topped twenty percent.
Industry Background
The pact follows a long-running tension between the drug companies and the British authorities over medicine costs and approval rates.
This friction were intensified by assertions that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
In recent months, several large drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
